Nuvectis Pharma (NVCT) Equity Ratio (2021 - 2026)

Nuvectis Pharma has disclosed Equity Ratio across 6 years of filings, most recently posting 0.56 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.56, down 19.45% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.56 (down 19.45% YoY), and the FY2025 annual result was 0.58, up 11.24% from the prior year.
• Equity Ratio came in at 0.56 for Q1 2026 at Nuvectis Pharma, down from 0.58 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.83 in Q1 2022 to a low of 0.52 in Q4 2024.
• The 5-year median for Equity Ratio is 0.7 (2025), against an average of 0.69.
• Across the five-year window, Equity Ratio soared 142.14% in 2022 and slipped 19.45% in 2026, its largest moves.
• Nuvectis Pharma's Equity Ratio stood at 0.7 in 2022, then retreated by 8.74% to 0.64 in 2023, then slipped by 17.92% to 0.52 in 2024, then gained by 11.24% to 0.58 in 2025, then decreased by 3.58% to 0.56 in 2026.
• The last three Equity Ratio figures came in at 0.56 (Q1 2026), 0.58 (Q4 2025), and 0.67 (Q3 2025), per Business Quant data.